Effect of Red Wine, White Wine and Beer on Contrast-Medium Induced Acute Kidney Injury
RenPro-II-WINE
Randomized Controlled Study for Evaluation of the Impact of Red Wine, White Wine and Beer Intake on Contrast-Medium Induced Acute Kidney Injury
1 other identifier
interventional
260
1 country
1
Brief Summary
Patients with impaired renal function are at elevated risk for development of contrast-medium induced acute kidney injury (CI-AKI). CI-AKI is associated with increased risk for cardiovascular morbidity and mortality. Effective CI-AKI prevention strategies are needed. The RenPro-II-WINE Trial was designed to test the hypothesis whether moderate red wine consumption prior to contrast-medium use is effective in CI-AKI prevention. Consecutive patients with impaired renal function undergoing elective coronary angiography will be assigned in one of four treatment arms: a. control patients receiving standard care b. patients receiving standard care plus red wine c. patients receiving standard care plus white wine d. patients receiving standard care plus beer This study will give important answers on how to prevent CI-AKI in patients with impaired renal function undergoing contrast media exposure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Mar 2012
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2012
CompletedFirst Submitted
Initial submission to the registry
March 22, 2012
CompletedFirst Posted
Study publicly available on registry
March 26, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedJuly 8, 2013
July 1, 2013
6 months
March 22, 2012
July 4, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
CI-AKI incidence
Increment of serum-creatinin of 0.5 mg/dl or of at least 25% in 48 hours after contrast medium intake from baseline.
<48 hours after contrast-medium exposure
Secondary Outcomes (1)
Biomarkers assessing acute kidney injury
<48 hours
Study Arms (4)
Red Wine
ACTIVE COMPARATORPatients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
White wine
ACTIVE COMPARATORBeer
ACTIVE COMPARATORControl
NO INTERVENTIONPatients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
Interventions
Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Eligibility Criteria
You may qualify if:
- age \>= 18 years
- impaired renal function (baseline estimated glomerular filtration rate of \<60 ml/min)
- at least three of following comorbidities: hypertension, diabetes mellitus without insulin therapy, heart failure NYHA III and/or left ventricular ejection fraction \<35%, peripheral artery disease, coronary artery disease
You may not qualify if:
- known alcohol addiction
- severe renal impairment (estimated glomerular filtration rate \<15 ml/min and/or in chronic dialysis program
- Recent (\<=30 days) contrast media exposure
- insulin therapy
- Patients enrolled in concomitant studies
- fertile women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Herzzentrum der Universität zu Köln
Cologne, 50937, Germany
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, Assistant Professor
Study Record Dates
First Submitted
March 22, 2012
First Posted
March 26, 2012
Study Start
March 1, 2012
Primary Completion
September 1, 2012
Study Completion
September 1, 2012
Last Updated
July 8, 2013
Record last verified: 2013-07